诺和诺德向FDA申请批准更高剂量Wegovy®注射液7.2 mg近日，诺和诺德宣布向美国食品药品监督管理局（FDA）递交更高剂量司美格鲁肽注射液7.2 mg补充新药申请（sNDA），拟在减少热量饮食和增加体力活动的基础上，用于成人肥胖症患者的长期体重管理依据CNPV加速项目，FDA受理申请后，预计将于1-2个月内完成审批。此项sNDA包括来自STEP UP试验的结果。STEP UP试验是为期72周...
Source Link诺和诺德向FDA申请批准更高剂量Wegovy®注射液7.2 mg近日，诺和诺德宣布向美国食品药品监督管理局（FDA）递交更高剂量司美格鲁肽注射液7.2 mg补充新药申请（sNDA），拟在减少热量饮食和增加体力活动的基础上，用于成人肥胖症患者的长期体重管理依据CNPV加速项目，FDA受理申请后，预计将于1-2个月内完成审批。此项sNDA包括来自STEP UP试验的结果。STEP UP试验是为期72周...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.